{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Moxifloxacin",
    "query": {
      "condition": "Moxifloxacin"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 107,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Moxifloxacin&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T16:23:55.448Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00437242",
      "title": "Odiparcil QT Definitive Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Fibrillation, Atrial",
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "Odiparcil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 54,
      "start_date": "2006-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-06-04",
      "last_synced_at": "2026-07-22T16:23:55.448Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00437242"
    },
    {
      "nct_id": "NCT02735603",
      "title": "Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Heart Repolarization"
      ],
      "interventions": [
        {
          "name": "Naltrexone HCl/bupropion HCl",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Orexigen Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 84,
      "start_date": "2016-04",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2016-11-01",
      "last_synced_at": "2026-07-22T16:23:55.448Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02735603"
    },
    {
      "nct_id": "NCT01775761",
      "title": "A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "TTR Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "Period 1",
          "type": "DRUG"
        },
        {
          "name": "Period 2",
          "type": "DRUG"
        },
        {
          "name": "Period 3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 42,
      "start_date": "2013-01",
      "completion_date": "2013-04",
      "has_results": false,
      "last_update_posted_date": "2013-05-21",
      "last_synced_at": "2026-07-22T16:23:55.448Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01775761"
    },
    {
      "nct_id": "NCT02027454",
      "title": "Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "GSK1265744",
          "type": "DRUG"
        },
        {
          "name": "GSK1265744 matching placebo",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 42,
      "start_date": "2014-01",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-06-16",
      "last_synced_at": "2026-07-22T16:23:55.448Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02027454"
    },
    {
      "nct_id": "NCT05927649",
      "title": "A TQTc Study for Omaveloxolone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Health Adult Subjects"
      ],
      "interventions": [
        {
          "name": "Omaveloxolone",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 30,
      "start_date": "2023-07-11",
      "completion_date": "2023-09-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-30",
      "last_synced_at": "2026-07-22T16:23:55.448Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05927649"
    },
    {
      "nct_id": "NCT00690313",
      "title": "Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Intravitreal Injection Patients"
      ],
      "interventions": [
        {
          "name": "Vigamox",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Illinois Retina Associates",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "21 Years to 100 Years"
      },
      "enrollment_count": 22,
      "start_date": "2008-08",
      "completion_date": "2011-04",
      "has_results": false,
      "last_update_posted_date": "2019-08-07",
      "last_synced_at": "2026-07-22T16:23:55.448Z",
      "location_count": 1,
      "location_summary": "Harvey, Illinois",
      "locations": [
        {
          "city": "Harvey",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00690313"
    },
    {
      "nct_id": "NCT00396084",
      "title": "Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Gatifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Isoniazid",
          "type": "DRUG"
        },
        {
          "name": "Levofloxacin",
          "type": "DRUG"
        },
        {
          "name": "Linezolid",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 70,
      "start_date": "2004-02-10",
      "completion_date": "2007-12-28",
      "has_results": true,
      "last_update_posted_date": "2018-11-08",
      "last_synced_at": "2026-07-22T16:23:55.448Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00396084"
    },
    {
      "nct_id": "NCT03258515",
      "title": "A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "AZD6094 200 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 45,
      "start_date": "2017-09-06",
      "completion_date": "2018-03-24",
      "has_results": false,
      "last_update_posted_date": "2020-02-20",
      "last_synced_at": "2026-07-22T16:23:55.448Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03258515"
    },
    {
      "nct_id": "NCT01069900",
      "title": "Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Intraabdominal Infections"
      ],
      "interventions": [
        {
          "name": "Moxifloxacin (Avelox, BAY12-8039)",
          "type": "DRUG"
        },
        {
          "name": "Ertapenem",
          "type": "DRUG"
        },
        {
          "name": "Amoxicillin/Clavulanate",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin placebo",
          "type": "DRUG"
        },
        {
          "name": "Ertapenem placebo",
          "type": "DRUG"
        },
        {
          "name": "Amoxicillin/Clavulanate placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Months to 17 Years"
      },
      "enrollment_count": 458,
      "start_date": "2010-07-21",
      "completion_date": "2015-01-21",
      "has_results": true,
      "last_update_posted_date": "2018-03-20",
      "last_synced_at": "2026-07-22T16:23:55.448Z",
      "location_count": 2,
      "location_summary": "San Diego, California • Springfield, Massachusetts",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Springfield",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01069900"
    },
    {
      "nct_id": "NCT01290900",
      "title": "A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Male Volunteers"
      ],
      "interventions": [
        {
          "name": "NXL104",
          "type": "DRUG"
        },
        {
          "name": "Ceftaroline",
          "type": "DRUG"
        },
        {
          "name": "Placebo Infusion",
          "type": "DRUG"
        },
        {
          "name": "Ceftazidime",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 54,
      "start_date": "2011-02",
      "completion_date": "2011-05",
      "has_results": false,
      "last_update_posted_date": "2017-09-01",
      "last_synced_at": "2026-07-22T16:23:55.448Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01290900"
    }
  ]
}